Abstract
Chemotherapy of trypanosomotid infections continues to present challenges. Treatment of Trypanosoma cruzi infections is virtually impossible, while treatment of Leishmaniasis and African tryponosomiasis is, at best, difficult - often involving toxic drugs based on heavy metals such as antimony and arsenic. As with several other parasites, much recent research has focused on defining metabolic differences between parasite and host that could represent good targets for chemotherapy. As Graeme Henderson and Alan Fairlamb explain, there is something strange about glutothione in trypanosomotids - which seems to offer a very promising chemotherapeutic target.
Original language | English |
---|---|
Pages (from-to) | 312-315 |
Number of pages | 4 |
Journal | Parasitology Today |
Volume | 3 |
Issue number | 10 |
DOIs | |
Publication status | Published - Oct 1987 |
ASJC Scopus subject areas
- Parasitology